Suppr超能文献

慢性血管紧张素 II 受体阻断可降低 2 型糖尿病患者的肾内血管阻力。

Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.

作者信息

Fliser Danilo, Wagner Kathrin-Kristin, Loos Astrid, Tsikas Dimitrios, Haller Hermann

机构信息

Department of Internal Medicine, Medical School Hannover, Germany.

出版信息

J Am Soc Nephrol. 2005 Apr;16(4):1135-40. doi: 10.1681/ASN.2004100852. Epub 2005 Feb 16.

Abstract

Increased (intra)renal activity of the renin-angiotensin system may cause a persistent increase in renovascular resistance and intraglomerular pressure in patients with diabetes, thus contributing to the development of diabetic renal damage. The effect of chronic angiotensin II subtype 1 receptor blockade on (intra)renal hemodynamics in patients with type 2 diabetes was examined in a double-blind parallel group study. Patients were treated with 40 mg of olmesartan (n = 19) or placebo (n = 16), and renal hemodynamics were assessed before and after 12 wk of treatment using inulin and para-aminohippurate clearance techniques. Olmesartan significantly reduced 24-h ambulatory systolic and diastolic BP (both P < 0.05). In parallel, effective renal plasma flow increased significantly from 602 +/- 76 to 628 +/- 87 ml/min per 1.73 m(2), whereas filtration fraction and renovascular resistance decreased significantly (all P < 0.05). With placebo treatment, effective renal plasma flow decreased and filtration fraction increased significantly (both P < 0.05). GFR was not affected by both treatments. Active plasma renin concentration increased considerably (P < 0.05) with olmesartan therapy but remained unchanged with placebo treatment. Nitric oxide metabolism (plasma nitrate and nitrite) and asymmetric dimethylarginine blood levels were not affected by olmesartan and placebo therapy. In contrast, plasma 8-isoprostane 15(S)-8-iso-prostaglandin F(2a) concentration, a biochemical marker of oxidative stress, decreased significantly (P < 0.05) with olmesartan treatment. Chronic angiotensin II subtype 1 receptor blockade decreases (intra)renal vascular resistance and increases renal perfusion despite significant BP reduction. In addition, it significantly reduces oxidative stress. These effects of angiotensin II receptor antagonists may contribute to their beneficial long-term renal effects in patients with type 2 diabetes.

摘要

肾素 - 血管紧张素系统(肾内)活性增加可能导致糖尿病患者肾血管阻力和肾小球内压力持续升高,从而促使糖尿病肾损害的发生。在一项双盲平行组研究中,检测了慢性血管紧张素II 1型受体阻断对2型糖尿病患者(肾内)血流动力学的影响。患者分别接受40mg奥美沙坦(n = 19)或安慰剂(n = 16)治疗,治疗12周前后使用菊粉和对氨基马尿酸清除技术评估肾血流动力学。奥美沙坦显著降低24小时动态收缩压和舒张压(均P < 0.05)。与此同时,有效肾血浆流量从每1.73m² 602±76显著增加至628±87ml/min,而滤过分数和肾血管阻力显著降低(均P < 0.05)。安慰剂治疗时,有效肾血浆流量下降,滤过分数显著增加(均P < 0.05)。两种治疗均未影响肾小球滤过率。奥美沙坦治疗后活性血浆肾素浓度显著升高(P < 0.05),而安慰剂治疗时保持不变。一氧化氮代谢(血浆硝酸盐和亚硝酸盐)和不对称二甲基精氨酸血水平不受奥美沙坦和安慰剂治疗影响。相反,氧化应激的生化标志物血浆8 - 异前列腺素15(S)- 8 - 异前列腺素F₂α浓度在奥美沙坦治疗后显著降低(P < 0.05)。尽管血压显著降低,但慢性血管紧张素II 1型受体阻断仍可降低(肾内)血管阻力并增加肾灌注。此外,它还能显著降低氧化应激。血管紧张素II受体拮抗剂的这些作用可能有助于其对2型糖尿病患者产生有益的长期肾脏效应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验